Characteristics of psychotic symptoms reported in patients between 13 and 25 years old
| Methylphenidate | Atomoxetine | Amphetamine drugs | ||||
| Reports | % | Reports | % | Reports | % | |
| Total | 221 | 100.0 | 115 | 100 | 169 | 100 |
| Age (years) | ||||||
| 13–17 | 147 | 66.5 | 66 | 57.4 | 73 | 43.2 |
| 18–25 | 74 | 33.5 | 49 | 42.6 | 96 | 56.8 |
| Sex | ||||||
| Female | 75 | 34.0 | 30 | 26.1 | 59 | 34.9 |
| Male | 146 | 66.0 | 85 | 73.9 | 110 | 65.1 |
| ADHD indication | 119 | 53.8 | 66 | 57.4 | 105 | 62.1 |
| Continent | ||||||
| Africa | 4 | 1.8 | 2 | 1.7 | 0 | 0.0 |
| Americas | 75 | 34.0 | 74 | 64.3 | 150 | 88.8 |
| Asia | 15 | 6.8 | 3 | 2.6 | 0 | 0.0 |
| Europe | 124 | 56.0 | 31 | 27.0 | 16 | 9.4 |
| Oceania | 3 | 1.4 | 5 | 4.3 | 3 | 1.8 |
| USA | 59 | 26.7 | 66 | 57.4 | 138 | 81.7 |
| Cases reported by healthcare professional | ||||||
| Physician | 108 | 48.9 | 57 | 49.6 | 43 | 25.4 |
| Pharmacist | 10 | 4.5 | 2 | 1.7 | 11 | 6.5 |
| Serious adverse effect | 172 | 77.8 | 66 | 57.4 | 140 | 82.8 |
ADHD, attention-deficit hyperactivity disorder.